Beta-Glucan Driven vs. Empirical Antifungal Therapy in Critically Ill Patients

(1-3)-Beta-D-Glucan Driven vs. Empirical Antifungal Therapy in High Risk Critically Ill Patients A Randomized Study

This study is aimed to compare the duration of standard anti fungal therapy in high risk ICU patients with a strategy driven by BetaDGlucan test result

Inclusion Criteria:

• ICU admission (minimum of 48 hours in ICU with an expected length of stay of at least 48 hours)
• Ongoing Mechanical Ventilation
• Presence of CVC
• Sepsis/Septic Shock development while receiving broad spectrum antibiotics
• Positivity of Candida Score or Candida Colonization Index in absence of septic shock

Exclusion Criteria:

• Complicated Candida Infection
• Already ongoing anti fungal therapy
• Beta Glucan test not available
• Absence of informed consent
• Immunesuppressive status (long-term immunesuppresive or steroids therapy; AIDS; WBC <1000/mmc or neutrophils <500/mmc)
• Pregnancy
• Already enrolled in other interventional studies